OwnershipPublicly listed · Nasdaq: CRSPSEC EDGAR company record and tickers file (Nasdaq: CRSP) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: CRSP, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
3developments published
—US federal obligations on record
2private-offering notices since 2019
Oct 19, 2026latest development
Timeline
- Oct 19, 2026 · Leadership change
CRISPR Therapeutics reports changes involving its directors or officers (Form 8-K, Item 5.02)
Regulatory filing - Aug 3, 2026 · Reported results
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Company-reported - May 4, 2026 · Reported results
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Company-reported
Profile
- Legal name
- CRISPR Therapeutics AG
- Listing
- Nasdaq CRSP
- SEC filer
- CIK 0001674416 ↗
- SEC industry code
- Biological Products, (No Diagnostic Substances)
- Incorporated
- Switzerland
- Coverage
- Filings + federal awards
Mix of developments
Watch CRISPR Therapeutics
Anything new from CRISPR Therapeutics lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestPrivate offerings reported to the SEC (Form D)
A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.